First Participant Dosed in BeCoMe-9 Trial of BE-101

Be Biopharma announced that a first participant was dosed in the BeCoMe-9 Trial of BE-101for hemophilia B. BE-101 is a first-in-class, engineered to insert the human factor IX (FIX) gene into primary human B cells for the treatment of hemophilia B. BE-101 aims to offer a transformative new therapeutic option by delivering long-lasting FIX levels, with the flexibility to be titratable and re-dosable, and without the need for preconditioning. 

Source: LA Kelley Communications, Inc., Communique, August 2025